Disease Landscape and Forecast Insights

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors; it is characterized by muscle…

Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…

The HIV therapy market is crowded with many approved antiretroviral therapies (ARVs). Growth in this market is being driven by the increasing acceptance of new, high-priced ARVs, particularly the…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

Several effective anti-inflammatory agents and bronchodilators are available for controlling mild or moderate asthma. However, despite the availability of long-acting muscarinic antagonists (LAMAs…

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-…

With a drug-treated population of over 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis market has been a lucrative space for drug…

Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the negative symptoms of schizophrenia (e.g., apathy,…

Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key vitiligo patient populations, covering 171 countries and more than…

Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report diagnosed prevalence of vitiligo for each country, as well…